Syndax Pharmaceuticals, Inc. (SNDX)
9.54
-0.05
(-0.52%)
USD |
NASDAQ |
Nov 12, 16:00
9.54
0.00 (0.00%)
After-Hours: 20:00
Syndax Pharmaceuticals Free Cash Flow (Quarterly) : -27.25M for Sept. 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -27.25M |
| June 30, 2026 | -30.31M |
| March 31, 2026 | -50.34M |
| December 31, 2025 | -69.54M |
| September 30, 2025 | -70.67M |
| June 30, 2025 | -87.80M |
| March 31, 2025 | -95.16M |
| December 31, 2024 | -57.39M |
| September 30, 2024 | -62.32M |
| June 30, 2024 | -71.64M |
| March 31, 2024 | -83.55M |
| December 31, 2023 | -41.35M |
| September 30, 2023 | -44.65M |
| June 30, 2023 | -35.37M |
| March 31, 2023 | -39.23M |
| December 31, 2022 | -22.89M |
| September 30, 2022 | -28.54M |
| June 30, 2022 | -40.31M |
| March 31, 2022 | -41.93M |
| December 31, 2021 | 100.58M |
| September 30, 2021 | -24.94M |
| June 30, 2021 | -24.04M |
| March 31, 2021 | -22.59M |
| December 31, 2020 | -15.63M |
| September 30, 2020 | -18.30M |
| Date | Value |
|---|---|
| June 30, 2020 | -21.41M |
| March 31, 2020 | -15.92M |
| December 31, 2019 | -12.73M |
| September 30, 2019 | -8.529M |
| June 30, 2019 | -12.52M |
| March 31, 2019 | -16.83M |
| December 31, 2018 | -15.06M |
| September 30, 2018 | -18.47M |
| June 30, 2018 | -15.15M |
| March 31, 2018 | -20.04M |
| December 31, 2017 | -12.76M |
| September 30, 2017 | -10.22M |
| June 30, 2017 | -11.80M |
| March 31, 2017 | -12.67M |
| December 31, 2016 | -10.42M |
| September 30, 2016 | -11.50M |
| June 30, 2016 | -6.963M |
| March 31, 2016 | -6.536M |
| September 30, 2014 | -2.602M |
| June 30, 2014 | -3.804M |
| March 31, 2014 | -4.512M |
| December 31, 2013 | -2.786M |
| September 30, 2013 | |
| March 31, 2013 | -1.485M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 10.26M |
| Emergent BioSolutions, Inc. | 96.80M |
| Incyte Corp. | -690.95M |
| Vertex Pharmaceuticals, Inc. | 545.80M |
| Travere Therapeutics, Inc. | 69.45M |